A Study of Participant Satisfaction and Safety With Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer
Clinical trial NCT01964391 · COMPLETED
Trial details
- NCT number
- NCT01964391
- Sponsor
- Hoffmann-La Roche
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2014-02-21
- Primary completion
- 2016-12-22
- Enrollment
- 174
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.